Back to Search Start Over

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Authors :
Hong Zhou
Li-Li Cai
Yan-Fang Lin
Jun-Jie Ma
Source :
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Publication Year :
2024
Publisher :
Nature Portfolio, 2024.

Abstract

Abstract Immune checkpoint inhibitors (ICIs) have become an important cornerstone of many tumour treatments. However, the toxicity profile of immune-chemotherapy combination treatment approaches among older adult cancer patients is still unclear. Patients with any cancer who received camrelizumab-based immunotherapy were eligible for inclusion. The primary endpoints were adverse events (AEs) and immune-related adverse events (irAEs), which were defined based on Naranjo's algorithm. Patients were stratified by age (≥ 70 years and

Details

Language :
English
ISSN :
20452322
Volume :
14
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Scientific Reports
Publication Type :
Academic Journal
Accession number :
edsdoj.ba3ea96789cf4016b93b9bca4d491e90
Document Type :
article
Full Text :
https://doi.org/10.1038/s41598-024-69944-w